Skinbiotherapeutics Share Discussion Threads

[parob] 02/5/2018 18:51

Shrewdie,I don't think yesterday's RNS got the attention it deserved as focus unexpectedly switched to OPTI following US media interest. Here's a repost of Cath's latest proactive interview which was BEFORE yesterday's news.hTTps://m.youtube.com/watch?v=HwcogXkbN2s

[shrewdmole] 02/5/2018 18:23

Parob

I think we will be at 30p or more pre trials.

Cath sounds uber positive and you can almost sense they are very deep into a possible deal already hence the doubling of the trial numbers.

S

[parob] 02/5/2018 17:58

News flow was pretty slow here for the first 6 months or so, almost non-existent, but we can look forward to plenty across all of their application areas over the coming months.

[bobalot] 02/5/2018 13:32

Yes, but volatility will increase and start to accelerate the share price from this level on stock shortage imo.

[onedayrodders] 02/5/2018 13:09

15p bid the new nosebleed level for traders ... still those who exited at 14p regretting now

[bobalot] 02/5/2018 12:45

ADVFN issued a BREAKOUT ALERT.

TAKE A LOOK AT TODAY'S BARCHART SHARE RATING ANALYSIS:

Overall Average: 96% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.

[onedayrodders] 02/5/2018 12:42

Yep indeed :O)

Very excited to see the strength in the SO baring in mind we are still haven't even started the trial yet

ODR

[parob] 02/5/2018 12:40

One year high. Blue skies above 18p. Chart looks great!

[bobalot] 02/5/2018 11:33

THE RISE IN THE UPWARD CHANNEL appears to be continuing with steady buying activity.

Thanks parob --- article is a nice one:

[parob] 02/5/2018 11:31

Northland Capital Partners Limited Morning Report: Skinbiotherapeutics PLC hTTps://www.directorstalk.net/northland-capital-partners-limited-morning-report-skinbiotherapeutics-plc-2/

[parob] 01/5/2018 18:07

This is what caught my attention:The six week study will be conducted on 120 female volunteers with self-assessed 'dry skin'. Initially the study was planned to be undertaken with 60 participants but this has now been doubled to make this one of the most substantial sized studies in this field.

[onedayrodders] 01/5/2018 17:18

Seems 14p is the nose bleed round number for the traders for a while

[bobalot] 01/5/2018 08:38

A copy of the RNS is on their website as follows:

[matt123d] 01/5/2018 08:24

Second attempt at 14p, would anticipate 20p pretty quickly if it holds.

[bobalot] 01/5/2018 08:15

That is really useful news---everything is moving in the right direction including patents....EXCELLENT.
Dr. Cath IS FULL OF SURPRISES.

[semper vigilans] 01/5/2018 07:35

Many thanks Daft.

[daftbat] 01/5/2018 07:30

SkinBioTherapeutics finalises plans for human study of cosmetic application and progresses manufacturing scale-up



Manchester, UK - 01 May 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, is pleased to provide the following update:

Human study

The design of the human study planned for Q3 2018 has now been finalised. This will be conducted independently by Alba Science Limited, a clinical research organisation based in Edinburgh, which has many years of experience in the field of cosmetic testing.

The six week study will be conducted on 120 female volunteers with self-assessed 'dry skin'. Initially the study was planned to be undertaken with 60 participants but this has now been doubled to make this one of the most substantial sized studies in this field.

The following measurements will be taken over the course of the study:

- visual assessment of skin dryness

- skin hydration (corneometry)

- skin barrier function (transepidermal water loss - TEWL)

Skin swab samples will also be taken at the beginning and end of the study to examine the effects of the technology on the skin microbiome.

The cream formulation of SkinBiotix® will be applied three times daily to delineated areas of the legs and measurements repeated after two and four weeks. Analysis of the data will take a further two weeks. Consequently, the entire study is likely to take around eight weeks.

The anticipated outcomes are that the hydration of the skin will be improved by the SkinBiotix® cream; the barrier function will be stronger (shown by a decrease in water loss across the skin barrier) and that the technology is safe for the skin microbiome. These are all characteristics of interest to partners for the development and commercialisation of a successful cosmetic product.

Manufacturing

The Company has made further progress with its lysate manufacturing process. A new method of manufacture that is scalable has been successfully trialled and results indicate no detrimental impact upon the active properties of the SkinBiotix® technology.

Further work is required to optimise the process to achieve manufacture on a commercial scale but the progress to date is encouraging.

Patent grants

The Company's first patent, covering the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease, which was granted in Australia in November 2017, has now been granted in New Zealand and Russia. While not deemed to be key jurisdictions, the Company is pleased to see progress in its patent portfolio. Active prosecution of the patent application in other locations including Europe, USA and China is ongoing.

Dr Cath O'Neill, CEO of SkinBioTherapeutics, commented:

"We are really pleased with the progress we have made across design of the human efficacy study and with the upscaling of the lysate manufacturing.

"We are determined to make the study as impactful as possible, which is why we have doubled its size. The cost impact is marginal, but the increase in the strength of the potential data and hence, to future partnering discussions, could be significant. Scaling up the manufacturing process is a key step in our development, and we are also moving this forward very well."

[semper vigilans] 01/5/2018 07:28

RNS showing on iii but not here yet?

[bobalot] 30/4/2018 14:45

The share price is holding very well right now during this consolidation cycle before moving up and beyond 14p and before impending news later this week perhaps.

[onedayrodders] 30/4/2018 14:24

Excellent volume and buying pressure over on OPTI ... could be good for sentiment here too.

Something definitely brewing and close over there !!!

yeah I know .. you've heard it all before

[slartybartfaster] 30/4/2018 12:23

Zedder, don't care for bs traders always finding the top and the bottom then rinse and repeat.

[bobalot] 30/4/2018 12:13

SkinBio might get a mention in nexts weeks magazine review about the skin microbiome imo.

5 big things we learned for beauty and personal care at in-cosmetics global 2018

[zedder] 30/4/2018 10:25

Despite the chart it did get close to 15p intraday. I certainly sold 35000 at 14.5p on 25th April.

[parob] 30/4/2018 09:32

Another attempt at 14p coming.

[onedayrodders] 30/4/2018 09:17

OPTI up as well .... has the microbiome penny finally dropped for the AIM masses